Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the progr ...

In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

And while nerandomilast does not cure pulmonary fibrosis (once established, lung damage does not regress), it represents a major step forward for the treatment of this condition.

SAN FRANCISCO — Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, lowered FVC decline vs. placebo in patients with progressive pulmonary fibrosis, according to results ...

The investigative phosphodiesterase 4B inhibitor appears better than placebo at protecting against decline in lung function over 1 year.

SAN FRANCISCO — Two doses of 52-week nerandomilast, a phosphodiesterase 4B inhibitor, reduced FVC decline vs. placebo in patients with idiopathic pulmonary fibrosis, according to results ...

Nerandomilast significantly reduces the decline in forced vital capacity in adults with progressive pulmonary fibrosis over 52 weeks, thereby slowing the progression of the condition.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Nerandomilast significantly slowed lung function decline in patients with IPF, with the 18 mg dose showing a 68.8 mL FVC decline reduction compared with placebo. The trial included 1177 patients ...

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC ...

Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopa ...

In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients with progressive pulmonary fibrosis over 52 weeks 2. The occurrence ...